Disturbances in slow-wave sleep are induced by models of bilateral inflammation, neuropathic, and postoperative pain, but not osteoarthritic pain in rats
Authors:
- Katharine L. ChuKCKatharine L. Chu
- Jun XuJXJun Xu
- Madhavi PaiMPMadhavi Pai
- He S. YangHYHe S. Yang
- Holly M. RobbHRHolly M. Robb
- Michael F. JarvisMJMichael F. Jarvis
- Richard J. RadekRRRichard J. Radek
- Steve McGaraughtySMSteve McGaraughty
- 1 July 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 154 (7) , 1092-1102
Abstract
Preclinical assessment of pain has typically relied on measuring animal responses to evoked stimulation. Because of inherent limitations of these assays, there is a need to develop measures of animal pain/discomfort that are objective, not experimentally evoked, and mimic the human condition. Patients with chronic pain manifest a variety of co-morbidities, one of which is disturbances in sleep. We used electroencephalography to objectively assess 4 rat models of pain (inflammatory/complete Freund's adjuvant [CFA], neuropathic/chronic constriction injury [CCI], postoperative/skin incision, osteoarthritis/monosodium iodoacetate [MIA]) for the occurrence of sleep disturbances. Four different measures of slow-wave sleep (SWS) were examined: amplitude of 1- to 4-Hz waves, total time spent in SWS, time spent in SWS-1, and time spent in SWS-2. Bilateral injuries were more likely to induce a sleep disturbance than unilateral injuries in the CFA, CCI, and skin incision assays. Sleep disturbances occurred in the deeper stage of SWS, as the amplitude of 1- to 4-Hz waves and time spent in SWS-2 were significantly decreased in all models except the osteoarthritis model. Sleep disturbances lasted for approximately 3 to 14days, depending on the model, and were resolved despite continued hypersensitivity to evoked stimulation. Morphine, gabapentin, diclofenac, and ABT-102 (TRPV1 antagonist) all improved sleep in the bilateral CFA assay at doses that did not significantly alter SWS in uninjured rats. Preclinical assessment of compounds should follow the path of clinical studies and take into account diverse aspects of the "pain condition." This would include evaluating nociceptive thresholds as well as other endpoints, such as cognition and sleep, that may be affected by the pathological state.Keywords
This publication has 75 references indexed in Scilit:
- Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated painEuropean journal of pain, 2012
- TRPV1-related modulation of spinal neuronal activity and behavior in a rat model of osteoarthritic painBrain Research, 2011
- Prevalence of sleep disturbance in patients with low back painEuropean Spine Journal, 2010
- Assessment of post-laparotomy pain in laboratory mice by telemetric recording of heart rate and heart rate variabilityBMC Veterinary Research, 2007
- Neuropathic pain symptoms relative to overall pain ratingThe Journal of Pain, 2004
- Sleep patterns over 21-day period in rats with chronic constriction of sciatic nerveBrain Research, 2003
- Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trialsClinical Therapeutics, 2003
- Neurological findings in complex regional pain syndromes - analysis of 145 casesActa Neurologica Scandinavica, 2000
- Measurement in pain therapy: is pain relief really the endpoint?Current Opinion in Anaesthesiology, 1998
- Sleep deprivation: Effect on sleep stages and EEG power density in manElectroencephalography and Clinical Neurophysiology, 1981